<DOC>
	<DOCNO>NCT00808951</DOCNO>
	<brief_summary>Resistance antimalarial drug represent major obstacle control malaria endemic country , sub-Saharan country change antimalarial drug policy new Artemisinin Containing Therapies . Burkina Faso change policy uncomplicated malaria Artemether-Lumefantrine ( AL ) Artesunate-Amodiaquine ( AQ+AS ) , still little available data safety efficacy treatment Burkina Faso ; treatment show efficacious , AL seem high occurrence recurrent malaria infection 28-day follow period . Thus , study aim compare safety efficacy AL AS-AQ ( 42-day follow-up ) , AND also compare vitro sensitivity , patient recurrent infection , result obtain vivo .</brief_summary>
	<brief_title>In Vivo Vitro Efficacy Antimalarial Treatments Children Burkina Faso</brief_title>
	<detailed_description>Plasmodium falciparum resistance antimalarial drug represent major drawback obstacle control malaria endemic country ; 's sub-Saharan country change antimalarial drug policy Artemisinin Containing Therapies ( ACT ) , produce rapid clinical parasitological cure , reduce gametocyte carriage rate generally well tolerate . Burkina Faso recently change policy treatment uncomplicated malaria , Chloroquine Artemether-Lumefantrine ( AL ) Artesunate-Amodiaquine ( AQ+AS ) . However , still little available data safety efficacy treatment Burkina Faso ; recent study carry Bobo Dioulasso show treatment extremely efficacious ( adjust treatment failure le 5 % ) AL show significantly high occurrence recurrent infection 28-day follow period . The high risk recurrent infection AL confirm subsequent trial compare AL AQ-SP dihydroartemisinin-piperaquine , far direct comparison AQ+AS AL complete , though study Nanoro , near Ouagadougou , ongoing . Thus , present study aim compare vivo safety efficacy AL AS-AQ ( 42-day follow-up ) , AND compare vitro sensitivity different ACT component , patient recurrent infection , result obtain vivo .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Age 6 59 month Weight &gt; 5 kg Monoinfection P. falciparum Parasitemia 4,000200,000 asexual parasite per µl Fever : &gt; 37.5 °C history fever precede 24 hour Haemoglobin &gt; 5.0 g/dl Signed informed consent parent guardians Parents ' guardian ' willingness ability comply study protocol duration trial . Participation clinical trial previous 30 day Known hypersensitivity study drug Severe and/or complicate malaria ( case refer BoboDioulasso University hospital treatment ) Danger sign : able drink breastfeed , vomit ( &gt; twice 24hours ) , recent history convulsion ( &gt; 1 24h ) , unconscious state , unable sit stand ; Known intercurrent illness condition would place subject undue risk interfere result study . Severe malnutrition ( weight height &lt; 70 % median NCHS/WHO reference )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Uncomplicated malaria</keyword>
	<keyword>P falciparum</keyword>
	<keyword>Children</keyword>
	<keyword>National treatment protocol</keyword>
	<keyword>Burkina Faso</keyword>
	<keyword>Artemether-lumefantrine</keyword>
	<keyword>Artesunate-amodiaquine</keyword>
	<keyword>In vivo efficacy</keyword>
	<keyword>In vitro efficacy</keyword>
</DOC>